PMPRB

The PMPRB protects and informs Canadians by ensuring that the prices of patented medicines sold in Canada are not excessive and by reporting on pharmaceutical trends.

Regional life sciences Organization letter

Subject: Request to postpone decision on July 15, 2021 PMPRB Guidelines changes

Date: October 14, 2021

BioAlberta's submission to PMPRB August

Response to: Consultations on the PMPRB’s proposed changes (July 15, 2021) to definition
of gap medicines, references to comparator countries and the international price tests for
grandfathered medicines and their line extensions

Date: August 31, 2021

BioAlberta's submission to PMPRB

Subject: Consultations on the PMPRB’s proposed changes to definition of Gap medicines and timeline for compliance

Date: February 15, 2021

BioAlberta's Submission to the House of Commons Standing Committee on Health (HESA)

RE: Study on the impacts of the PMPRB

Date: November 6, 2020

Letter to Members of PMPRB

Subject: BioAlberta’s submission to PMPRB guidelines consultation

Date: February 14, 2020

Letter to Health Canada and House of Commons

Subject: Regarding Proposed Changes to PMPRB Regulations 

Date: August 24, 2019

Letter to Prime Minister Justin Trudeau

Subject: On PMPRB reform, political leadership and evidence-based approach needed 

Date: April 1, 2019

Letter to Prime Minister's Office Increasing Concerns regarding Proposed Changes

Subject: Regarding Proposed Reforms to the Patented Medicine Prices Review Board(PMPRB)Regulations

Date: March 7, 2019

BioAlberta Letter to PMPRB

RE: Representation concerning proposed changes to patented medicines regulations

Date: February 14, 2018

Letter from BioAlberta to Alberta Minister Bilous on PMPRB

RE: Serious concerns with proposed changes to Patented Medicines Regulations

Date: January 30, 2018

Letter from BioAlberta to Alberta Minister Hoffman on PMPRB

RE: Serious concerns with proposed changes to Patented Medicines Regulations

Date: January 30, 2018

Letter from BioAlberta to AP MLAs on PMPRB

RE: Serious concerns with proposed changes to Patented Medicines Regulations

Date: January 30, 2018

Letter from BioAlberta to Conservative MPs on PMPRB

RE: Serious concerns with proposed changes to Patented Medicines Regulations

Date: January 30, 2018

Letter from BioAlberta to Health Canada on PMPRB

RE: Serious concerns with proposed changes to Patented Medicines Regulations

Date: January 30, 2018

Letter from BioAlberta to Innovation, Science and Economic Development Canada on PMPRB

RE: Serious concerns with proposed changes to Patented Medicines Regulations

Date: January 30, 2018

RE: Serious concerns with proposed changes to Patented Medicines Regulations

Date: January 30, 2018

Letter from BioAlberta to Liberal MPs on PMPRB

RE: Serious concerns with proposed changes to Patented Medicines Regulations

Date: January 30, 2018

Letter from BioAlberta to NDP MPs on PMPRB

RE: Serious concerns with proposed changes to Patented Medicines Regulations

Date: January 30, 2018


Letter from BioAlberta to PMO on PMPRB

RE: Serious concerns with proposed changes to Patented Medicines Regulations

Date: January 30, 2018

Letter from BioAlberta to UCP MLAs on PMPRB

RE: Serious concerns with proposed changes to Patented Medicines Regulations

Date: January 30, 2018

BIOTECanada Letter to Minister Bains

RE: PMPRB

Date: January 22, 2018

Letter to Prime Minister's Office follow-up on Proposed Changes

Subject: Regarding Patented Medicines Regulations Consultations

Date: October 17, 2017

Patented Medicines Price Review Board Consultation Presentation

Subject: A BioAlberta Briefing for Edmonton Mayor Don Iveson

Date: July 2017

Letter to Patented Medicines Regulations Consultations

Re: Response to Patented Medicines Regulations Consultations

Date: June 28, 2017

Letter to Mayor Don Iveson

Subject: Regarding Health Canada conducting a review affecting the Life Sciences Industry

Date: June 27, 2017